Novartis AG

LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH HIDS (HYPER-IGD SYNDROME) - INTERIM ANALYSIS OF THE RELIANCE REGISTRY (2022) Oommen P, Kallinich T, Rech J, Blank N, Weber-Arden J, Kuemmerle-Deschner JB Conference contribution Multicomponent intervention to prevent mobility disability in frail older adults: randomised controlled trial (SPRINTT project) (2022) Bernabei R, Landi F, Calvani R, Cesari M, Del Signore S, Anker SD, Bejuit R, et al. Journal article Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL) (2022) Neven P, Fasching P, Chia S, Jerusalem G, De Laurentiis M, Im SA, Petrakova K, et al. Conference contribution Assessment of side effects (SEs) impacting quality of life (QoL) in patients (pts) undergoing treatment (tx) for advanced breast cancer (ABC) in clinical practice: A real-world (RW) multi-country survey (2022) Cardoso F, Rihani J, Aubel D, De Courcy J, Harmer V, Harbeck N, Casas A, et al. Conference contribution [Lu-177]Lu-DOTA-TATE as First-line Therapy for Patients With Grade 2 and 3 Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): The NETTER-2 Study (2022) Singh S, Pavel ME, Kunz PL, De Herder W, Herrmann K, D'Amelio AM, Santoro P, et al. Conference contribution Treatment-Free Remission in Real-World Chronic Myeloid Leukemia Patients: Insights from German Hematology Practices (2022) Dengler J, Tesch H, Jentsch-Ullrich K, Gerhardt A, Schulte C, Lipke J, Loewe G, Kiani A Journal article Physician-reported Clinical Unmet Needs, Burden and Treatment Patterns of Paediatric Psoriasis Patients: A US and EU Real-world Evidence Study (2022) Seyger MM, Augustin M, Sticherling M, Bachhuber T, Fang J, Hetherington J, Lucas J, et al. Journal article Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2− Advanced Breast Cancer in the MONALEESA-3 Trial (2022) Jerusalem G, Delea TE, Martin M, De Laurentiis M, Nusch A, Beck JT, Chan A, et al. Journal article Patient-reported outcomes and burden of disease in paediatric patients with psoriasis: real-world data from the EU5 and USA (2022) Seyger M, Paller A, Sticherling M, Bachhuber T, Fang J, Hetherington J, Lucas J, et al. Conference contribution Pooled safety analysis from two phase III studies of secukinumab in paediatric patients with moderate-to-severe plaque psoriasis up to week 52 (2022) Sticherling M, Nikkels AF, Hamza AM, Kwong P, Ortmann CE, Papanastasiou P, Forrer P, Keefe D Conference contribution